State of 340B in 2024: Biggest Developments Expected this Year

Key Points from the 2023 Year in Review:

Presented By:

Justin Rolling
VP of National Sales

Anthony Velasquez
Chief Product Officer

© 2024 PharmaForce. All rights reserved.

Join our webinar for a comprehensive exploration of the current status of the 340B program, featuring a review of major industry trends from 2023 and key developments anticipated for 2024.

We'll discuss what entities should expect and prepare for in the upcoming year, addressing crucial questions about manufacturer restrictions and potential Congressional actions.

HRSA's Enhanced Authority: Notably, four entities were removed from the 340B Program, signaling a more assertive approach by HRSA.

Federal Appeals Court Opinions: Stay tuned for anticipated opinions from two federal appeals courts that could significantly impact the program.

Genesis v. HRSA Patient Definition Battle: Explore the ongoing legal battle and its potential implications for the 340B Program.

Best in KLAS^®. Three years and counting.

We’re proud to report that compared to the four largest TPAs in 340B, PharmaForce emerged as the overall best 340B Third Party Administrator with “A” ratings in every category, including overall performance, Culture, Loyalty, Operations, Product, Relationship, and Value—scoring a 91/100.

Leadership Change at OPA: We'll examine the potential impact of the change in leadership at the Office of Pharmacy Affairs on the program.

Who Should Attend:

Upcoming Challenges:

Congress's considerations and potential legislation in the works for 2024

Manufacturer Restrictions: A review of the past year's events and their current impact on the 340B Program participants.

• Anyone interested in learning more about the 340B program 
• Covered entities participating in the 340B program
• Finance Directors
• Program Managers
• Pharmacy Directors